Skip to main content
EJNMMI Research

Table 4 Differences between iRECIST and iPERCIST classification, observed in 11/28 patients, in relation to survival

From: Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

iRECIST

iPERCIST

Nb of patients

Survival in days, mean (± SD)a

SD

PMR

5

520 (± 104)

SD

PMD

2

360 (± 234)

PD

SMD

2

573 (± 204)

PR

CMR

1

967

CR

PMR

1

717

  1. iRECIST Immune RECIST, iPERCIST Immune PERCIST, SD Stable disease, PD progressive disease, PR partial response, CR complete response, PMR partial metabolic response, PMD progressive metabolic disease, SMD stable metabolic disease, CMR complete metabolic response
  2. aNB: mean survival for the population study (n = 28) = 479 days (± 248)
Back to article page